These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2091057)

  • 21. [ORL brachytherapy. Brachytherapy of epidermoid carcinoma of the oral cavity].
    Haie-Meder C; Marsiglia H; Mamelle G; Wibault P; Lartigau E; Gerbaulet A
    Bull Cancer Radiother; 1995; 82(2):186-90. PubMed ID: 7546889
    [No Abstract]   [Full Text] [Related]  

  • 22. [Cancer and radiotherapy(3). Radiobiology for radiotherapy].
    Ando K
    Iyodenshi To Seitai Kogaku; 1982 Apr; 20(2):122-9. PubMed ID: 6752496
    [No Abstract]   [Full Text] [Related]  

  • 23. Radiotherapy for the treatment of primary vaginal cancer.
    Samant R; Tam T; Dahrouge S; E C
    Radiother Oncol; 2005 Nov; 77(2):133-6. PubMed ID: 16260055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer.
    Kucera H; Pötter R; Knocke TH; Baldass M; Kucera E
    Wien Klin Wochenschr; 2001 Jan; 113(1-2):58-62. PubMed ID: 11233470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recent possibilities in high-dose rate brachytherapy].
    Kneschaurek P
    Rontgenpraxis; 1989 Nov; 42(11):392-7. PubMed ID: 2686045
    [No Abstract]   [Full Text] [Related]  

  • 26. [Use of brachytherapy in the treatment of malignant tumors].
    Kanaev SV; Turkevich VG; Baranov SB
    Vopr Onkol; 2005; 51(2):245-52. PubMed ID: 16223012
    [No Abstract]   [Full Text] [Related]  

  • 27. [A proposal for dosage and volume specification and documentation in HDR brachytherapy].
    Krieger H; Baltas D; Kneschaurek P
    Strahlenther Onkol; 1996 Oct; 172(10):527-42. PubMed ID: 8966670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
    Nickers P; Thissen B; Jansen N; Deneufbourg JM
    Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Interstitial radiation therapy in the combined treatment of malignant tumors].
    Androsov NS; Nechushkin MI
    Vopr Onkol; 1995; 41(2):92-3. PubMed ID: 7483455
    [No Abstract]   [Full Text] [Related]  

  • 30. Endobronchial brachytherapy.
    Villanueva AG; Lo TC; Beamis JF
    Clin Chest Med; 1995 Sep; 16(3):445-54. PubMed ID: 8521699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose-rate brachytherapy for large prostate volumes (> or =50cc)-Uncompromised dosimetric coverage and acceptable toxicity.
    Monroe AT; Faricy PO; Jennings SB; Biggers RD; Gibbs GL; Peddada AV
    Brachytherapy; 2008; 7(1):7-11. PubMed ID: 18299109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerated partial breast irradiation: where do we go from here?
    Haffty BG
    Breast J; 2005; 11(5):303-5. PubMed ID: 16174148
    [No Abstract]   [Full Text] [Related]  

  • 33. [Dose, time and volume factors in interstitial therapy of tongue neoplasms with cf-252].
    Vtiurin BM; Ivanov VN; Abdulkadyrov SA; Ivanova LF
    Med Radiol (Mosk); 1982 Feb; 27(2):3-8. PubMed ID: 7070237
    [No Abstract]   [Full Text] [Related]  

  • 34. [Intraluminal and interstitial radiation therapy].
    Kumpulainen E; Lahtinen T; Johansson R
    Duodecim; 1996; 112(18):1710-4. PubMed ID: 10596169
    [No Abstract]   [Full Text] [Related]  

  • 35. Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base.
    Karakoyun-Celik O; Norris CM; Tishler R; Mahadevan A; Clark JR; Goldberg S; Devlin P; Busse PM
    Head Neck; 2005 May; 27(5):353-61. PubMed ID: 15726587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inter-institutional variation of implant activity for permanent prostate brachytherapy.
    Aronowitz JN; Crook JM; Michalski JM; Sylvester JE; Merrick GS; Mawson C; Pratt D; Naidoo D; Butler WM; Karolczuk K
    Brachytherapy; 2008; 7(4):297-300. PubMed ID: 18786866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of dose-volume parameters, endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI-based brachytherapy.
    Georg P; Kirisits C; Goldner G; Dörr W; Hammer J; Pötzi R; Berger D; Dimopoulos J; Georg D; Pötter R
    Radiother Oncol; 2009 May; 91(2):173-80. PubMed ID: 19243846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Heterogeneity of neoplasms, radiosensitivity interval and optimal therapeutic dose].
    Kholin VV
    Med Radiol (Mosk); 1975 Jan; 20(1):52-4. PubMed ID: 1128194
    [No Abstract]   [Full Text] [Related]  

  • 39. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy.
    Al-Salihi O; Mitra A; Payne H
    Prostate Cancer Prostatic Dis; 2006; 9(4):370-3. PubMed ID: 16832383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Dosimetric consequences of increased seed strength for I-125 prostate implants. Radiother Oncol. 2003 Sep;68(3):295-7.
    Lee WR
    Radiother Oncol; 2004 Feb; 70(2):209-10; author reply 210. PubMed ID: 15028411
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.